Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Instil Bio, Inc.NASDAQ: TIL
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $12K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $24K. Over 3 fiscal years it compounded at -55.3% a year.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly cost of revenue holds near $12K or moves back toward the trailing-twelve-month quarterly average of $6K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 534K USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 534K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 5.99M | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -96.8% is the 7th highest of 8, against a peer median of -26.6%.
- Over three fiscal years its annual growth of -55.3% compares with a peer median of -41.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.23M USD | -18.4% | +80.2% | 30.1% | |
| LTM Mar 2026 | €7.26M EUR | +133.7% | — | 24746.3% | |
| LTM Mar 2026 | $1.82M USD | -36.2% | — | 182.0% | |
| LTM Mar 2026 | $711K USD | +14.3% | — | — | |
| LTM Mar 2026 | $151K USD | — | — | — | |
| LTM Mar 2026 | CA$119.31K CAD | -26.6% | -38.5% | — | |
| LTM Mar 2026 | $65K USD | -83.2% | -45.2% | 0.9% | |
| LTM Mar 2026 | $24K USD | -96.8% | -55.3% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $5K USD | -100.0% | -71.8% | — |
| Peer median (excluding TIL) | — | -26.6% | -41.9% | 106.0% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 5.99M | 0 | 0 | 534K |
| Gross Profit | 0 | (5.99M) | 0 | 0 | (534K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 107.25M | 141.06M | 39.6M | 11.84M | 10M |
| Selling, General & Admin | 51.31M | 62.24M | 47.55M | 44.21M | 27.22M |
| Operating Expenses | 155.56M | 200.18M | 159.17M | 73.54M | 52.37M |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| EBITDA | (152.51M) | (217.38M) | (147.12M) | (62.53M) | (65.01M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (155.56M) | (206.17M) | (159.17M) | (73.54M) | (52.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 80K | 3.66M | 8.87M | 6.99M | 3.86M |
| Interest Expense | 0 | 1.88M | 5.21M | 8.99M | 5.83M |
| Other Income / Expenses | (1.2M) | (19.08M) | 3.08M | (594K) | (18.47M) |
| Income Before Tax | (156.76M) | (225.25M) | (156.09M) | (74.14M) | (71.37M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39K | (2.07M) | 0 | 0 | 0 |
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| EPS (Diluted) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| Weighted Avg Shares | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
| Weighted Avg Shares (Diluted) | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.